Extended Spectrum Beta Lactamase Testing
Test in Focus
Fecal microbiota transplantation, or stool transplantation, is a process wherein fecal matter is collected from a healthy person and transplanted into the gastrointestinal tract of a patient. It's a safe therapy that's used to treat severe or refractory Clostridium difficile infection.
Problems can occur, however, when donor stool is found to have harmful multi-drug resistant gram-negative extended spectrum beta lactamase (ESBL) bacteria that could jeopardize the success and safety of fecal microbiota transplants -- especially in patients who carry the bacteria in their gut without getting sick.
In this “Test in Focus” episode of Mayo Clinic Laboratories’ “Answers From the Lab” podcast, clinical microbiologist and pathologist Audrey Schuetz, M.D., outlines how Mayo Clinic Laboratories’ new culture based ESBL testing panel screens for the colonization or carriage of ESBL bacteria.
“These bacteria are concerning for a few different reasons,” Dr. Schuetz says. “The first is that colonization with this bacterium has been associated with increased risk of infection in certain patient populations, especially those with hematologic malignancies. The second reason that we're concerned about this is that when a person has a multi-drug resistant bacterium, such as an ESBL and actually gets sick from this, that really limits the antibiotic treatment options for that patient because of the increased resistance. The third reason is more of a public health type of risk or concern in that the antibiotic resistance genes that are carried by these bacteria are easily passed from bacteria to bacteria.” Listen to learn more about how Mayo Clinic Laboratories’ new ESBL testing panel expands upon previous testing methods to improve outcomes for fecal microbiota transplant patients.
Note: Podcasts will not playback on Internet Explorer. Please use an alternative web browser, or listen from your mobile device on a preferred listening app.
Screening for colonization of extended-spectrum beta-lactamase (ESBL)-producing organisms in stool. Screening fecal microbiota transplant donor feces for ESBL-producing organisms. This test is not intended for medicolegal use.
Patient preparation: Do not use barium or bismuth before specimen collection.
Supplies: C and S Vial (T058)
Specimen Type: Preserved Feces
Container/Tube: Cary-Blair or modified Cary-Blair transport system is required.
Commercially available transport system specific for recovery of enteric pathogens from fecal specimens (15 mL of nonnutritive transport medium containing phenol red as a pH indicator. Submit sample in original Cary Blair medium container (not an aliquot of Cary Blair medium).
Specimen Volume: Representative portion of feces; 1 gram or 5 mL
Analytic time: 4 days
Days performed: Monday through Sunday
Alicia Algeciras, Ph.D., describes Mayo Clinic Laboratories’ new blood test to detect NFLC, or neurofilament light chain protein. NFLC is a biomarker for several neurodegenerative conditions. The new assay can determine if a patient’s cognitive decline is due to a neurodegenerative condition or some other, reversible condition — while avoiding the need for more-invasive testing of cerebral spinal fluid.
Paul Jannetto, Ph.D., and Loralie Langman, Ph.D., discuss Mayo Clinic Laboratories' unique approach to urine drug testing for addiction rehabilitation. Designed to guide and monitor therapy, the comprehensive profile tests for the most commonly used substances, including alcohol and nicotine, for a complete picture of a patient’s substance use.